Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Palmer

Physician Assistant Lansing, MI Physician Assistant

NPI 1023362639 CMS profile 11069892

4333 W St Joe Hwy, Lansing, MI 48917

Open in the dashboard

General payments

$17,095

1,045 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Palmer of Lansing, MI is reported in the CMS Open Payments database as having received $17,095 across 1,045 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,544 182
2024 General $3,521 221
2023 General $3,580 221
2022 General $3,353 193
2021 General $3,097 228

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Palmer
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Timothy Palmer were reported at $3,544. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Timothy Palmer Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,097 $132 $37–$438 $132
2022 $3,353 $155 $48–$522 $149
2023 $3,580 $167 $52–$557 $160
2024 $3,521 $178 $55–$600 $164
2025 $3,544 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,402 273 payments
  2. Amgen Inc. $3,136 177 payments
  3. AbbVie, Inc. $2,672 209 payments
  4. UCB, Inc. $1,675 80 payments
  5. Novartis Pharmaceuticals Corporation $1,084 59 payments
  6. AstraZeneca Pharmaceuticals LP $1,001 49 payments
  7. E.R. Squibb & Sons, L.L.C. $640 23 payments
  8. ANI Pharmaceuticals, Inc. $456 22 payments
  9. Pfizer Inc. $397 28 payments
  10. Lilly USA, LLC $273 14 payments
  11. Other $2,360 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,653 1,038 payments
  2. Education $442 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,936 223 payments
  2. RINVOQ $2,012 182 payments
  3. SIMPONI ARIA $1,310 122 payments
  4. Cimzia $1,205 60 payments
  5. SAPHNELO $966 47 payments
  6. Otezla $908 48 payments
  7. Enbrel Inflammation $817 49 payments
  8. COSENTYX $757 35 payments
  9. Enbrel Inflammation $680 45 payments
  10. STELARA $678 54 payments
  11. Other $8,796 522 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

2,612

Median for Physician Assistant: 241

Drug cost

$2,268,696

Median for Physician Assistant: $4,110

Branded share of claims

29.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 71 $532,226
Humira(Cf) Pen Adalimumab Brand 73 $499,955
Humira Adalimumab Brand 26 $341,988
Rinvoq Upadacitinib Brand 26 $166,455
Enbrel Etanercept Brand 27 $159,902
Tremfya Guselkumab Brand 12 $152,490
Xeljanz Xr Tofacitinib Citrate Brand 19 $107,997
Enbrel Mini Etanercept Brand 13 $94,384
Simponi Golimumab Brand 13 $78,394
Otezla Apremilast Brand 11 $51,893

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$521 26 —
SKYRIZI
$316 — —
COSENTYX
$264 — —
Enbrel
$218 111 —
SAPHNELO
$217 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,045 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record